Skip to main content
Back
Watch Compare

Clearside Biomedical, Inc.

Data quality: 100%
CLSDQ
OTC Manufacturing Chemicals
$0.26
▼ $0.04 (-13.33%)
Mkt Cap: 1.47 M
Price
$0.28
Mkt Cap
1.47 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Revenue declined -32.24% annually over 5 years
Negative free cash flow of -21.75 M
Revenue growth is decelerating — 1Y growth trails 5Y average by 47.53%

Growth

Revenue Growth (5Y)
-32.24%
Below sector avg (1.82%)
Revenue (1Y)-79.77%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
N/A
ROIC-171.49%
Net Margin-780.90%
Op. Margin-689.76%

Safety

Debt / Equity
N/A
Current Ratio2.98
Interest CoverageN/A

Valuation

PE (TTM)
-0.06
Above sector avg (-1.49)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -0.1 -1.5
P/B — 1.6
ROE % — -54.0
Net Margin % -780.9 -41.5
Rev Growth 5Y % -32.2 1.8
D/E — 0.3

Analyst Price Target

1 analyst
No analyst coverage available

Earnings Estimates

No forward estimates available

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q32025 -$0.60 -$1.14 -90.0%
Q22025 -$1.52 -$0.06 +96.1%
Q12025 -$1.60 -$1.65 -3.1%
Q42024 -$1.55 -$1.50 +3.2%

All Fundamental Metrics
Growth
Revenue Growth (1Y) -79.77% Revenue Growth (3Y) 11.98%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -32.24% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3.33 M Net Income (TTM) -26.00 M
ROE N/A ROA -192.76%
Gross Margin N/A Operating Margin -689.76%
Net Margin -780.90% Free Cash Flow (TTM) -21.75 M
ROIC -171.49% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.98
Interest Coverage N/A Asset Turnover 0.25
Working Capital 5.48 M Tangible Book Value -53.95 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.06 Forward P/E N/A
P/B Ratio N/A P/S Ratio 0.44
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1478.56%
Market Cap 1.47 M Enterprise Value -5.33 M
Per Share
EPS (Diluted TTM) -3.71 Revenue / Share 0.64
FCF / Share -4.15 OCF / Share -4.07
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 13.61% FCF Conversion 83.65%
SBC-Adj. FCF -25.07 M Growth Momentum -47.53

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1.66 M 8.23 M 1.33 M 29.58 M 7.89 M
Net Income -34.35 M -32.49 M -32.95 M 376,000.0 -18.21 M
EPS (Diluted) -0.47 -0.53 -0.55 0.01 —
Gross Profit — — — — —
Operating Income -28.88 M -24.84 M -30.28 M -627,000.0 -17.94 M
EBITDA — — — — —
R&D Expenses 18.59 M 20.85 M 19.63 M 18.54 M 15.07 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 25.13 M 34.02 M 51.30 M 42.90 M 19.32 M
Total Liabilities 63.98 M 49.93 M 40.70 M 4.93 M 10.56 M
Shareholders' Equity -38.86 M -15.91 M 10.61 M 37.98 M 8.76 M
Total Debt — — — — 3.82 M
Cash & Equivalents 20.02 M 28.92 M 48.26 M 30.44 M 17.29 M
Current Assets 21.27 M 30.12 M 49.40 M 42.14 M 18.12 M
Current Liabilities 4.79 M 6.81 M 5.78 M 4.64 M 9.94 M